|
| | Term | p value | Genes |
|
| KEGG | Inflammatory bowel disease (IBD) | 6.29E − 05 | TGFB2; MAF; IL12A; HLA-DQB1 |
| Leishmaniasis | 1.88E − 03 | TGFB2; IL12A; HLA-DQB1 |
| Th1 and Th2 cell differentiation | 3.50E − 03 | MAF; IL12A; HLA-DQB1 |
| Toxoplasmosis | 6.21E − 03 | TGFB2; IL12A; HLA-DQB1 |
| Allograft rejection | 6.98E − 03 | IL12A; HLA-DQB1 |
| Type I diabetes mellitus | 8.88E − 03 | IL12A; HLA-DQB1 |
| Malaria | 1.14E − 02 | TGFB2; IL12A |
| Mineral absorption | 1.23E − 02 | STEAP2; MT1E |
| MAPK signaling pathway | 1.63E − 02 | TGFB2; KITLG; PDGFD; EFNA5 |
| Tuberculosis | 2.14E − 02 | TGFB2; IL12A; HLA-DQB1 |
| Proteoglycans in cancer | 2.88E − 02 | FZD1; TGFB2; TWIST1 |
| Rap1 signaling pathway | 3.07E − 02 | KITLG; PDGFD; EFNA5 |
| TGF-beta signaling pathway | 3.57E − 02 | TGFB2; NBL1 |
| Rheumatoid arthritis | 3.64E − 02 | TGFB2; HLA-DQB1 |
| Amoebiasis | 4.01E − 02 | TGFB2; IL12A |
| Hematopoietic cell lineage | 4.09E − 02 | KITLG; HLA-DQB1 |
| Ras signaling pathway | 4.13E − 02 | KITLG; PDGFD; EFNA5 |
| Melanogenesis | 4.39E − 02 | FZD1; KITLG |
| Chagas disease (American trypanosomiasis) | 4.55E − 02 | TGFB2; IL12A |
| BioCarta | Wnt/LRP6 Signalling_Homo sapiens_h_wnt-lrp6Pathway | 2.29E − 02 | FZD1 |
| Role of Parkin in Ubiquitin-Proteasomal Pathway_Homo sapiens_h_parkinPathway | 2.61E − 02 | GPR37 |
| NO2-dependent IL 12 Pathway in NK cells_Homo sapiens_h_no2il12Pathway | 2.93E − 02 | IL12A |
| Melanocyte Development and Pigmentation Pathway_Homo sapiens_h_melanocytepathway | 4.21E − 02 | KITLG |
| IL12 and Stat4 Dependent Signaling Pathway in Th1 Development_Homo sapiens_h_IL12Pathway | 4.84E − 02 | IL12A |
| Reactome | Transmembrane transport of small molecules_Homo sapiens_R-HSA-382551 | 1.35E − 02 | SLC12A2; ATP7B; SLC15A2; ABCC5; STEAP2; MCOLN2 |
| Hyaluronan biosynthesis and export_Homo sapiens_R-HSA-2142850 | 1.64E − 02 | ABCC5 |
| Cation-coupled Chloride cotransporters_Homo sapiens_R-HSA-426117 | 2.29E − 02 | SLC12A2 |
| Peptide ligand-binding receptors_Homo sapiens_R-HSA-375276 | 2.60E − 02 | GPR37; ANXA1; RLN2 |
| Formyl peptide receptors bind formyl peptides and many other ligands_Homo sapiens_R-HSA-444473 | 2.61E − 02 | ANXA1 |
| Relaxin receptors_Homo sapiens_R-HSA-444821 | 2.61E − 02 | RLN2 |
| Muscle contraction_Homo sapiens_R-HSA-397014 | 2.70E − 02 | ANXA1; KCNIP4; KCNK2 |
| Response to metal ions_Homo sapiens_R-HSA-5660526 | 3.57E − 02 | MT1E |
| Metallothioneins bind metals_Homo sapiens_R-HSA-5661231 | 3.57E − 02 | MT1E |
| Tandem pore domain potassium channels_Homo sapiens_R-HSA-1296346 | 3.89E − 02 | KCNK2 |
| EPH-Ephrin signaling_Homo sapiens_R-HSA-2682334 | 3.93E − 02 | EFNA5; KALRN |
| Purine salvage_Homo sapiens_R-HSA-74217 | 4.21E − 02 | ADK |
| Transport of inorganic cations/anions and amino acids/oligopeptides_Homo sapiens_R-HSA-425393 | 4.24E − 02 | SLC12A2; SLC15A2 |
| MHC class II antigen presentation_Homo sapiens_R-HSA-2132295 | 4.55E − 02 | KIF5C; HLA-DQB1 |
| GO BP | Copper ion import (GO:0015677) | 2.96E − 04 | ATP7B; STEAP2 |
| Digestive tract development (GO:0048565) | 4.13E − 04 | TGFB2; PKDCC; GATA2 |
| Embryonic organ development (GO:0048568) | 7.55E − 04 | TGFB2; KITLG; PKDCC |
| Copper ion transport (GO:0006825) | 9.51E − 04 | ATP7B; STEAP2 |
| Embryonic cranial skeleton morphogenesis (GO:0048701) | 1.10E − 03 | SIX1; TWIST1 |
| Embryonic digestive tract development (GO:0048566) | 1.96E − 03 | TGFB2; PKDCC |
| Embryonic skeletal system morphogenesis (GO:0048704) | 2.37E − 03 | SIX1; TWIST1 |
| Regulation of phosphatidylinositol 3-kinase signaling (GO:0014066) | 2.44E − 03 | TGFB2; PDGFD; TWIST1 |
| Regulation of angiogenesis (GO:0045765) | 2.85E − 03 | TGFB2; RLN2; TWIST1; GATA2 |
| Iron ion import across plasma membrane (GO:0098711) | 1.96E − 02 | STEAP2 |
| Carbohydrate phosphorylation (GO:0046835) | 3.57E − 02 | ADK |
| Muscle cell migration (GO:0014812) | 3.57E − 02 | SIX1 |
| Ribonucleoside monophosphate biosynthetic process (GO:0009156) | 4.52E − 02 | ADK |
| Purine-containing compound salvage (GO:0043101) | 4.52E − 02 | ADK |
| Positive regulation of glycolytic process (GO:0045821) | 4.84E − 02 | PFKFB4 |
| Positive regulation of coenzyme metabolic process (GO:0051197) | 4.84E − 02 | PFKFB4 |
| Positive regulation of cellular catabolic process (GO:0031331) | 4.87E − 02 | PFKFB4; TWIST1 |
| GO MF | Transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding (GO:0001228) | 1.46E − 02 | EBF1; SIX1; GATA2; MEIS2 |
| Neurotrophin TRKA receptor binding (GO:0005168) | 1.96E − 02 | EFNA5 |
| Transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding (GO:0001077) | 2.05E − 02 | EBF1; SIX1; MEIS2 |
| NAADP-sensitive calcium-release channel activity (GO:0072345) | 2.29E − 02 | MCOLN2 |
| Type II transforming growth factor beta receptor binding (GO:0005114) | 2.61E − 02 | TGFB2 |
| Phosphofructokinase activity (GO:0008443) | 2.61E − 02 | PFKFB4 |
| Carbohydrate kinase activity (GO:0019200) | 4.21E − 02 | ADK |
| Ubiquitin protein ligase activity involved in ERAD pathway (GO:1904264) | 4.21E − 02 | TMEM129 |
| Platelet-derived growth factor receptor binding (GO:0005161) | 4.21E − 02 | PDGFD |
| Nucleoside kinase activity (GO:0019206) | 4.52E − 02 | ADK |
|
